NCT05161507 is a clinical trial of Magseed in Breast Carcinoma, sponsored by University Hospital Ostrava.

Who is sponsoring NCT05161507?

NCT05161507 is sponsored by University Hospital Ostrava.

What drugs are being tested in NCT05161507?

Interventions in NCT05161507: Magseed, Magtrace, Axillary lymph node metastasis - needle biopsy.

What condition does NCT05161507 study?

NCT05161507 studies Breast Carcinoma, Breast Carcinoma Metastatic in Lymph Node.

Is NCT05161507 still recruiting?

NCT05161507 is currently completed. Last updated 26 January 2024.

Last reviewed 2024-01-26 · How we verify

NCT05161507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magseed and Magtrace Localization for Breast Cancer

Completed Last updated 26 January 2024

What this trial tests

trial testing Magseed in Breast Carcinoma in 70 participants. Completed in 31 December 2023.

Timeline

4 May 2020

Primary endpoint
31 December 2021

31 December 2023

Quick facts

Lead sponsor	University Hospital Ostrava
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	4 May 2020
Primary completion	31 December 2021
Estimated completion	31 December 2023
Sites	1 location across Czechia

Drugs / interventions tested

Magseed
Magtrace — full drug profile →
Axillary lymph node metastasis - needle biopsy

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →
Breast Carcinoma Metastatic in Lymph Node — all drugs for Breast Carcinoma Metastatic in Lymph Node →

Sponsor

University Hospital Ostrava

Who can join

18 and older, any sex, with Breast Carcinoma or Breast Carcinoma Metastatic in Lymph Node. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare the efficacy of the Sentimag localization system and its tracer Magtrace, superparamagnetic iron oxide nanoparticles, as a tracer in sentinel node biopsy in breast cancer with Tc99 in a single-center prospective study. The other part of the study will be the implantation of the smallest non-radioactive seed, Magseed, in the non-palpable breast cancer lesions. Another part of the study will be the implantation of Magseed in the positive axillary lymph nodes in patients diagnosed with clinically positive lymph nodes that will receive neoadjuvant systemic therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.
Gawne PJ, Ferreira M, Papaluca M, Grimm J, et al · · 2023 · cited 112× · PMID 39022623 · DOI 10.1038/s41578-023-00581-x
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.
Oehler JB, Rajapaksha W, Albrecht H. · · 2024 · cited 16× · PMID 39063977 · DOI 10.3390/jpm14070723
Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.
Wu L, He C, Zhao T, Li T, et al · · 2024 · cited 6× · PMID 38918821 · DOI 10.1186/s12951-024-02644-9

Verify or expand the search:

Other trials of Magseed

Trials testing the same drug.

NCT06463600 — Tumour Localisation With Magnetic Clip Before Neoadjuvant Chemotherapy. · NA · recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other University Hospital Ostrava trials

Trials by the same sponsor.

NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
NCT07041086 — Prehospital ECPR in Moravia Silesia Region · recruiting
NCT07009652 — Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05161507 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Ostrava
Last refreshed: 26 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing